Department of Thoracic Oncosurgery-2, Jilin Province Tumor Hospital, Changchun, China.
Oral and Maxillofacial Surgery, Jilin Province Tumor Hospital, Changchun, China.
Kaohsiung J Med Sci. 2021 Jun;37(6):505-512. doi: 10.1002/kjm2.12365. Epub 2021 Feb 8.
Multidrug resistance (MDR) of chemotherapy is one of the significant concerns in cancer therapy. Here in our study, cisplatin (DDP) and oleanolic acid (OA) were co-loaded in mesoporous silica nanoparticles (Nsi) to construct DDP/OA-Nsi and solve the DDP-resistance in lung cancer therapy. The cytotoxicity and apoptosis assays demonstrated that in DDP-resistant A549/DDP cells, the cytotoxicity of DDP/OA-Nsi was significantly higher than that of free DDP or DDP single delivery system (DDP-Nsi). The intracellular drug accumulation study revealed that the intracellular DDP concentration in the DDP/OA-Nsi group was also higher than that in free DDP and DDP-Nsi groups. In the A549/DDP xenograft tumor model, DDP/OA-Nsi showed the best anticancer effect. In summary, DDP/OA-Nsi was a promising drug delivery system to solve MDR in lung cancer therapy.
多药耐药(MDR)是癌症治疗中的一个重大问题。在本研究中,顺铂(DDP)和齐墩果酸(OA)被共载于介孔硅纳米粒子(Nsi)中,构建了 DDP/OA-Nsi,以解决肺癌治疗中的 DDP 耐药问题。细胞毒性和细胞凋亡实验表明,在 DDP 耐药的 A549/DDP 细胞中,DDP/OA-Nsi 的细胞毒性明显高于游离 DDP 或 DDP 单一给药系统(DDP-Nsi)。细胞内药物积累研究表明,DDP/OA-Nsi 组的细胞内 DDP 浓度也高于游离 DDP 和 DDP-Nsi 组。在 A549/DDP 异种移植肿瘤模型中,DDP/OA-Nsi 显示出最佳的抗癌效果。综上所述,DDP/OA-Nsi 是一种有前途的药物传递系统,可解决肺癌治疗中的 MDR 问题。